ダルナビル (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ダルナビル" in Japanese language version.

refsWebsite

Global rank Japanese rank

13nih.gov

4^th place

24^th place

7doi.org

2^nd place

6^th place

6web.archive.org

1^st place

3pmda.go.jp

6,690^th place

394^th place

3worldcat.org

5^th place

19^th place

3fda.gov

447^th place

1,043^rd place

2drugs.com

399^th place

1,603^rd place

2hivandhepatitis.com

low place

1europa.eu

68^th place

425^th place

1nikkeibp.co.jp

1,415^th place

95^th place

1handle.net

102^nd place

78^th place

1hiv.gov

low place

1prezista.com

low place

1acs.org

1,248^th place

1,765^th place

1asm.org

3,555^th place

2,938^th place

1springer.com

274^th place

596^th place

acs.org

pubs.acs.org

Leonis, Georgios; Czyżnikowska, Żaneta; Megariotis, Grigorios; Reis, Heribert; Papadopoulos, Manthos G. (2012-06-25). “Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps” (英語). Journal of Chemical Information and Modeling 52 (6): 1542–1558. doi:10.1021/ci300014z. ISSN 1549-9596.

asm.org

journals.asm.org

King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Wigerinck, Piet; de Béthune, Marie-Pierre; Schiffer, Celia A. (2004-11). “Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor” (英語). Journal of Virology 78 (21): 12012–12021. doi:10.1128/JVI.78.21.12012-12021.2004. ISSN 0022-538X.

doi.org

Leonis, Georgios; Czyżnikowska, Żaneta; Megariotis, Grigorios; Reis, Heribert; Papadopoulos, Manthos G. (2012-06-25). “Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps” (英語). Journal of Chemical Information and Modeling 52 (6): 1542–1558. doi:10.1021/ci300014z. ISSN 1549-9596.
King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Wigerinck, Piet; de Béthune, Marie-Pierre; Schiffer, Celia A. (2004-11). “Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor” (英語). Journal of Virology 78 (21): 12012–12021. doi:10.1128/JVI.78.21.12012-12021.2004. ISSN 0022-538X.
Lascar, R. M.; Benn, P. (2009). “Role of darunavir in the management of HIV infection”. HIV AIDS (Auckl) 1: 31–39. doi:10.2147/hiv.s5397. PMC 3218677. PMID 22096377.
Li, Dan; Zhang, Ying; Zhao, Run-Ning; Fan, Song; Han, Ju-Guang (2014-02). “Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation” (英語). Journal of Molecular Modeling 20 (2): 2122. doi:10.1007/s00894-014-2122-y. ISSN 1610-2940.
MacArthur, Rodger D (2007). “Darunavir: promising initial results”. The Lancet 369 (9568): 1143–1144. doi:10.1016/S0140-6736(07)60499-1. PMID 17416241.
Liu, F.; Kovalevsky, A.Y. (2008). “Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir”. J. Mol. Biol. 381 (1): 102–115. doi:10.1016/j.jmb.2008.05.062. PMC 2754059. PMID 18597780.
Eron, J (2000). “HIV-1 Protease Inhibitors”. Clinical Infectious Diseases 30: 160–170. doi:10.1086/313853. PMID 10860901.

drugs.com

“Darunavir (Prezista) Use During Pregnancy”. Drugs.com (2018年10月23日). 2020年4月21日閲覧。
“Darunavir”. The American Society of Health-System Pharmacists. 2016年11月10日時点のオリジナルよりアーカイブ。2016年11月28日閲覧。

europa.eu

ema.europa.eu

“Prezista EPAR”. European Medicines Agency (EMA). 2020年4月21日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。

fda.gov

"FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs". U.S. Food and Drug Administration (FDA) (Press release). 2016年11月13日時点のオリジナルよりアーカイブ。2016年11月10日閲覧。
“HIV/AIDS Historical Time Line 2000 - 2010”. U.S. Food and Drug Administration (2018年1月5日). 2019年6月1日時点のオリジナルよりアーカイブ。2020年4月21日閲覧。

accessdata.fda.gov

“Drug Approval Package: Prezista (Darumavir) NDA #021976”. U.S. Food and Drug Administration (FDA) (2006年9月6日). 2020年4月21日閲覧。

handle.net

hdl.handle.net

World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. (2019). hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO

hiv.gov

clinicalinfo.hiv.gov

“Darunavir / Cobicistat”. AIDSinfo. U.S. Department of Health and Human Services. 2021年6月15日閲覧。

hivandhepatitis.com

hivandhepatitis.com Archived 2007-07-13 at the Wayback Machine., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL Archived 2009-07-19 at the Wayback Machine..
hivandhepatitis.com Archived 2007-07-13 at the Wayback Machine., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL Archived 2009-05-19 at the Wayback Machine..

nih.gov

pubmed.ncbi.nlm.nih.gov

Lefebvre, E.; Schiffer, C. A. (2008). “Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of Darunavir”. AIDS Rev. 10 (3): 131–142. PMC 2699666. PMID 18820715.
Lascar, R. M.; Benn, P. (2009). “Role of darunavir in the management of HIV infection”. HIV AIDS (Auckl) 1: 31–39. doi:10.2147/hiv.s5397. PMC 3218677. PMID 22096377.
MacArthur, Rodger D (2007). “Darunavir: promising initial results”. The Lancet 369 (9568): 1143–1144. doi:10.1016/S0140-6736(07)60499-1. PMID 17416241.
Liu, F.; Kovalevsky, A.Y. (2008). “Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir”. J. Mol. Biol. 381 (1): 102–115. doi:10.1016/j.jmb.2008.05.062. PMC 2754059. PMID 18597780.
Eron, J (2000). “HIV-1 Protease Inhibitors”. Clinical Infectious Diseases 30: 160–170. doi:10.1086/313853. PMID 10860901.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Prezista- darunavir tablet, film coated Prezista- darunavir suspension”. DailyMed (2019年6月6日). 2020年4月21日閲覧。

files.aidsinfo.nih.gov

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. (18 December 2019) 2020年4月21日閲覧。.

nikkeibp.co.jp

medical.nikkeibp.co.jp

日経メディカル. “耐性が生じにくいHIVプロテアーゼ阻害薬”. 日経メディカル. 2021年6月15日閲覧。

pmda.go.jp

info.pmda.go.jp

“プリジスタ錠600mg／プリジスタナイーブ錠800mg 添付文書”. www.info.pmda.go.jp. PMDA. 2021年6月15日閲覧。
“プレジコビックス配合錠添付文書”. www.info.pmda.go.jp. PMDA. 2021年6月15日閲覧。
“シムツーザ配合錠添付文書”. www.info.pmda.go.jp. PMDA. 2021年6月15日閲覧。

prezista.com

“Drug Monograph, Prezista”. 2016年11月11日時点のオリジナルよりアーカイブ。2021年6月15日閲覧。

springer.com

link.springer.com

Li, Dan; Zhang, Ying; Zhao, Run-Ning; Fan, Song; Han, Ju-Guang (2014-02). “Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation” (英語). Journal of Molecular Modeling 20 (2): 2122. doi:10.1007/s00894-014-2122-y. ISSN 1610-2940.

web.archive.org

“Darunavir”. The American Society of Health-System Pharmacists. 2016年11月10日時点のオリジナルよりアーカイブ。2016年11月28日閲覧。
hivandhepatitis.com Archived 2007-07-13 at the Wayback Machine., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL Archived 2009-07-19 at the Wayback Machine..
hivandhepatitis.com Archived 2007-07-13 at the Wayback Machine., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL Archived 2009-05-19 at the Wayback Machine..
“Drug Monograph, Prezista”. 2016年11月11日時点のオリジナルよりアーカイブ。2021年6月15日閲覧。
"FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs". U.S. Food and Drug Administration (FDA) (Press release). 2016年11月13日時点のオリジナルよりアーカイブ。2016年11月10日閲覧。
“HIV/AIDS Historical Time Line 2000 - 2010”. U.S. Food and Drug Administration (2018年1月5日). 2019年6月1日時点のオリジナルよりアーカイブ。2020年4月21日閲覧。

worldcat.org

search.worldcat.org

Leonis, Georgios; Czyżnikowska, Żaneta; Megariotis, Grigorios; Reis, Heribert; Papadopoulos, Manthos G. (2012-06-25). “Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps” (英語). Journal of Chemical Information and Modeling 52 (6): 1542–1558. doi:10.1021/ci300014z. ISSN 1549-9596.
King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Wigerinck, Piet; de Béthune, Marie-Pierre; Schiffer, Celia A. (2004-11). “Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor” (英語). Journal of Virology 78 (21): 12012–12021. doi:10.1128/JVI.78.21.12012-12021.2004. ISSN 0022-538X.
Li, Dan; Zhang, Ying; Zhao, Run-Ning; Fan, Song; Han, Ju-Guang (2014-02). “Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation” (英語). Journal of Molecular Modeling 20 (2): 2122. doi:10.1007/s00894-014-2122-y. ISSN 1610-2940.